Publication | Open Access
Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation
16
Citations
21
References
2019
Year
Clinical Disease ActivityAutoimmune DiseaseDisease ProgressionNeurological DisorderMedicineImmunologyClinical TrialsNeurologyMultiple SclerosisImmunotherapyNeuroimmunologyRisk FactorsHealth Sciences
| Year | Citations | |
|---|---|---|
Page 1
Page 1